Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Proqr Therapeutics (PRQR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 440,820
  • Shares Outstanding, K 38,873
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,570 K
  • 60-Month Beta 0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +12.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.07 +0.36%
on 04/22/19
16.07 -30.84%
on 04/05/19
-3.89 (-25.93%)
since 03/22/19
3-Month
11.07 +0.36%
on 04/22/19
16.99 -34.61%
on 02/04/19
-4.48 (-28.74%)
since 01/22/19
52-Week
3.20 +247.19%
on 04/24/18
24.00 -53.71%
on 11/05/18
+7.56 (+212.96%)
since 04/20/18

Most Recent Stories

More News
ProQR to Present at Three Scientific Conferences in April

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming...

PRQR : 11.14 (-1.76%)
New Research: Key Drivers of Growth for Quintana Energy Services, ProQR Therapeutics N.V, Tetraphase Pharmaceuticals, Biomerica, Heat Biologics, and Bellerophon Therapeutics -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Quintana Energy Services Inc. (NYSE:QES),...

HTBX : 1.11 (-2.63%)
BMRA : 2.36 (-3.28%)
PRQR : 11.14 (-1.76%)
BLPH : 0.66 (+1.54%)
QES : 5.14 (+5.98%)
TTPH : 1.05 (-0.94%)
ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius,...

PRQR : 11.14 (-1.76%)
ProQR Announces Annual Meeting of Shareholders

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that...

PRQR : 11.14 (-1.76%)
ProQR Initiates Dosing in Phase II/III Eye Disorder Study

ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

PRQR : 11.14 (-1.76%)
EXEL : 20.35 (-2.63%)
CLSN : 2.36 (+0.85%)
FCSC : 2.17 (-3.13%)
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the...

PRQR : 11.14 (-1.76%)
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the...

PRQR : 11.14 (-1.76%)
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines...

PRQR : 11.14 (-1.76%)
ProQR to Present at Cowen Health Care Conference

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that...

PRQR : 11.14 (-1.76%)
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus

The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.

CELG : 93.41 (-0.37%)
PRQR : 11.14 (-1.76%)
MDCO : 27.80 (-0.79%)
ALNY : 82.08 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PRQR with:

Business Summary

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the...

See More

Key Turning Points

2nd Resistance Point 12.29
1st Resistance Point 11.82
Last Price 11.14
1st Support Level 11.02
2nd Support Level 10.69

See More

52-Week High 24.00
Fibonacci 61.8% 16.05
Fibonacci 50% 13.60
Fibonacci 38.2% 11.15
Last Price 11.14
52-Week Low 3.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar